Busl KM, Bleck TP. Treatment of neuroterrorism. Neurotherapeutics. 2012;9(1):139–57.
Vatansever F, Ferraresi C, de Sousa MV, Yin R, Rineh A, Sharma SK, Hamblin MR. Can biowarfare agents be defeated with light? Virulence. 2013;4(8):796–825.
Clarke SC. Bacteria as potential tools in bioterrorism, with an emphasis on bacterial toxins. Br J Biomed Sci. 2005;62(1):40–6.
Bioterrorism overview. Centers for Disease Control and Prevention website. Updated February 12, 2007. http://emergency.cdc.gov/bioterrorism/overview.asp. Accessed 2 Jan 2016.
Darling RG, Woods JB. Medical management of biological casualties handbook. 5th ed. Fort Detrick, MD: US Army Medical Research Institute of Infectious Diseases; 2004. p. 80–91 (appendix I).
Madsen JM. Toxins as weapons of mass destruction. A comparison and contrast with biological-warfare and chemical-warfare agents. Clin Lab Med. 2001;21:593–605.
Marks JD. Medical aspects of biologic toxins. Anesthesiol Clin North Am. 2004;22:509–32, vii.
Yinon A. Introduction to toxins. In: Brener B, Catz L, Rubinstok A, et al., editors. The biology book: medical aspects and responses [Hebrew]. Netanya: SAREL Logistics Solutions& Products for Advanced Medicine; 2002. p. 109–12.
Centers for Disease Control and Prevention. Botulism: information and guidance for clinicians. Updated June 14, 2006. http://www.bt.cdc.gov/agent/Botulism/clinicians. Accessed 2 Jan 2016.
Keller JE, Neale EA, Oyler G, Adler M. Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett. 1999;456:137–42.
Dembek ZF, Smith LA, Rusnak JM. Botulinum toxin. In: Dembek ZF, editor. Medical aspects of biological warfare. Washington, DC: Office of the Surgeon General, US Army Medical Department Center and School; Borden Institute, Walter Reed Army Medical Center; 2007. p. 337–53.
State of Israel, Ministry of Health. The Israeli doctrine for botulism [Hebrew]. Updated May, 2011. http://www.health.gov.il/Subjects/emergency/preparation/DocLib/tora/BIO_TORA_BOTOLISM.pdf. Accessed 2 Jan 2016.
Villar R, Elliott S, Davenport K. Botulism: the many faces of botulinum toxin and its potential for bioterrorism. Infect Dis Clin North Am. 2006;20:313–27.
Centers for Disease Control and Prevention. Botulism in the United States (1899–1996). Handbook for epidemiologists, clinicians, and laboratory workers. Atlanta, GA: US Department of Health, Education, and Welfare, CDC, 1998.
Barr JR, Moura H, Boyer AE, et al. Botulinum neurotoxin detection and differentiation by mass spectrometry. Emerg Infect Dis. 2005;11(10):1578–83.
Boyer AE, Moura H, Woolfitt AR, et al. From the mouse to the mass spectrometer: detection and differentiation of the endoproteinase activities of botulinum neurotoxins A–G by mass spectrometry. Anal Chem. 2005;77(13):3916–24.
Rosen O, Feldberg L, Gura S, Zichel R. Improved detection of botulinum type E by rational design of a new peptide substrate for endopeptidase-mass spectrometry assay. Anal Biochem. 2014;456:50–2.
Rosen O, Feldberg L, Gura S, Zichel R. A new peptide substrate for enhanced BoNT/B detection by endopep-LC-MS-MS/MRM assay. Anal Biochem. 2015;473:7–10.
Rosen O, Feldberg L, Gura S, et al. Early, real-time medical diagnosis of botulism by endopeptidase-mass spectrometry. Clin Infect Dis. 2015;61(12):e58–61.
Arnon SS, Schechter R, Inglesby TV, Working Group on Civilian Biodefense, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001;285:1059–70.
Centers for Disease Control and Prevention (CDC). Notice of CDC’s discontinuation of investigational pentavalent (ABCDE) botulinum toxoid vaccine for workers at risk for occupational exposure to botulinum toxins. MMWR Morb Mortal Wkly Rep. 2011;60:1454–5.
Pinchuk IV, Beswick EJ, Reyes VE. Staphylococcal enterotoxins. Toxins. 2010;2:2177–97.
Rajagopalan G, Sen MM, Singh M, et al. Intranasal exposure to staphylococcal enterotoxin B elicitsan acute systemic inflammatory response. Shock. 2006;25:647–56.
Rusnak JM, Kortepeter M, Ulrich R, Poli M, Boudreau E. Laboratory exposures to staphylococcal enterotoxin B. Emerg Infect Dis. 2004;10:1544–9.
McKay DM. Bacterial superantigens: provocateurs of gut dysfunction and inflammation? Trends Immunol. 2001;22:497–501.
Foster TJ. Immune evasion by staphylococci. Nat Rev Microbiol. 2005;3:948–58.
Fraser JD, Proft T. The bacterial superantigen and superantigen-like proteins. Immunol Rev. 2008;225:226–43.
Gill DM. Bacterial toxins: a table of lethal amounts. Microbiol Rev. 1982;46:86–94.
Papageorgiou AC, Acharya KR. Microbial superantigens: from structure to function. Trends Microbiol. 2000;8:69–75.
Kappler J, Kotzin B, Herron L, et al. V beta-specific stimulation of human T cells by staphylococcal toxins. Science. 1989;244:811–3.
Mantis NJ. Vaccines against the category B toxins: staphylococcal enterotoxin B, epsilon toxin and ricin. Adv Drug Deliv Rev. 2005;57:1424–39.
Ohlsen K, Lorenz U. Immunotherapeutic strategies to combat staphylococcal infections. Int J Med Microbiol. 2010;300:402–10.
Kumar S, Ménoret A, Ngoi SM, Vella AT. The systemic and pulmonary immune response to staphylococcal enterotoxins. Toxins (Basel). 2010;2:1898–912.
Musch MW, Petrof EO, Kojima K, Ren H, McKay DM, Chang EB. Bacterial superantigen-treated intestinal epithelial cells upregulate heat shock proteins 25 and 72 and are resistant to oxidantcytotoxicity. Infect Immun. 2004;72:3187–94.
Cook E, Wang X, Robiou N, Fries BC. Measurement of staphylococcal enterotoxin B in serum and culture supernatant with a capture enzyme-linked immunosorbent assay. Clin Vaccine Immunol. 2007;14:1094–101.
Soto CM, Martin BD, Sapsford KE, Blum AS, Ratna BR. Toward single molecule detection of staphylococcal enterotoxin B: mobile sandwich immunoassay on gliding microtubules. Anal Chem. 2008;80:5433–40.
Yang M, Kostov Y, Bruck HA, Rasooly A. Gold nanoparticle-based enhanced chemiluminescence immunosensor for detection of staphylococcal enterotoxin B (SEB) in food. Int J Food Microbiol. 2009;133:265–71.
Woody MA, Krakauer T, Stiles BG. Staphylococcal enterotoxin B mutants (N23 K and F44S): biological effects and vaccine potential in a mouse model. Vaccine. 1997;15:133–9.
Krakauer T. Chemotherapeutics targeting immune activation by staphylococcal superantigens. Med Sci Monit. 2005;11:290–5.
Yang X, Buonpane RA, Moza B, et al. Neutralization of multiple staphylococcal superantigens by a single-chain protein consisting of affinity-matured, variable domain repeats. J Infect Dis. 2008;198:344–8.
Alves GG, Machado de Ávila RA, Chávez-Olórtegui CD, Lobato FC. Clostridium perfringens epsilon toxin: the third most potent bacterial toxin known. Anaerobe. 2014;30:102–7.
Popoff MR. Epsilon toxin: a fascinating pore-forming toxin. FEBS J. 2011;278(23):4602–15.
Stiles BG, Barth G, Barth H, Popoff MR. Clostridium perfringens epsilon toxin: a malevolent molecule for animals and man? Toxins (Basel). 2013;5(11):2138–60.
Fernandez Miyakawa ME, Zabal O, Silberstein C. Clostridium perfringens epsilon toxin is cytotoxic for human renal tubular epithelial cells. Hum Exp Toxicol. 2011;30(4):275–82.
Barkley Brunett L. Clostridium perfringens toxin (epsilon toxin) attack. In: Ciottone GR, Anderson PD, editors. Disaster medicine. 1st ed. Maryland Heights: Mosby Inc.; 2006. p. 705.
Hunter SE, Clarke IN, Kelly DC, Titball RW. Cloning and nucleotide sequencing of the Clostridium perfringens epsilon-toxin gene and its expression in Escherichia coli. Infect Immun. 1992;60(1):102–10.
Adamson RH, Ly JC, Fernandez-Miyakawa M, et al. Clostridium perfringens epsilon-toxin increases permeability of single perfused microvessels of rat mesentery. Infect Immun. 2005;73(8):4879–87.
Finnie JW. Pathogenesis of brain damage produced in sheep by Clostridium perfringens type depsilon toxin: a review. Aust Vet J. 2003;81(4):219–21.
Finnie JW, Manavis J, Blumbergs PC. Aquaporin-4 in acute cerebral edema produced by Clostridium perfringens type depsilon toxin. Vet Pathol. 2008;45(3):307–9.
Miyamoto O, Minami J, Toyoshima T, et al. Neurotoxicity of Clostridium perfringens epsilon-toxin for the rat hippocampus via the glutamatergic system. Infect Immun. 1998;66(6):2501–8.
Miyamoto O, Sumitani K, Nakamura T, et al. Clostridium perfringens epsilon toxin causes excessive release of glutamate in the mouse hippocampus. FEMS Microbiol Lett. 2000;189(1):109–13.
Layana JE, Fernandez-Miyakawa ME, Uzal FA. Evaluation of different fluids for detection of Clostridium perfringens type D epsilon toxin in sheep with experimental enterotoxemia. Anaerobe. 2006;12:204–6.
Seyer A, Fenaille F, Feraudet-Tarisse C, et al. Rapid quantification of clostridial epsilon toxin in complex food and biological matrixes by immunopurification and ultraperformance liquid chromatography-tandem mass spectrometry. Anal Chem. 2012;84:5103–9.
Payne DW, Williamson ED, Havard H, Modi N, Brown J. Evaluation of a new cytotoxicity assay for Clostridium perfringens type D epsilon toxin. FEMS Microbiol Lett. 1994;116:161–8.
McClain MS, Cover TL. Functional analysis of neutralizing antibodies against Clostridium perfringens epsilon-toxin. Infect Immun. 2007;75(4):1785–93.
Titball RW. Clostridium perfringens vaccines. Vaccine. 2009;27(Suppl 4):D44–7.
Paddle BM. Therapy and prophylaxis of inhaled biological toxins. J Appl Toxicol. 2003;23(3):139–70.
Mayor S. UK doctors warned after ricin poison found in police raid. BMJ. 2003;326(7381):126.
Poli MA, Roy C, Huebner KD, et al. Ricin. In: Dembek ZF, editor. Medical aspects of biological warfare. Washington, DC: Office of the Surgeon General; 2007. p. 323–35.
Centers for Disease Control and Prevention. Facts about ricin. Updated May 9, 2013. http://emergency.cdc.gov/agent/ricin/facts.asp. Accessed 2 Jan 2016.
Bradberry SM, Dickers KJ, Rice P, Griffiths GD, Vale JA. Ricin poisoning. Toxicol Rev. 2003;22:65–70.
Moran-Gilad J, Tusk-Helerman L, Fogel I, et al. Ricin and abrin as potential bio-terror agents [Hebrew]. J Isr Millitry Med. 2010;7:124–6.
Greenfield RA, Brown BR, Hutchins JB, et al. Microbiological, biological, and chemical weapons of warfare and terrorism. Am J Med Sci. 2002;323:326–40.
Gu LQ, Ding S, Gao C. Aptamer-encoded nanoporefor ultrasensitive detection of bioterrorist agent ricin at single-molecule resolution. In: Conf Proc IEEE Eng Med Biol Soc. 2009. 2009, pp 6699–702.
O’Hara JM, Brey RN III, Mantis NJ. Comparative efficacy of two leading candidate ricin toxin a subunit vaccines in mice. Clin Vaccine Immunol. 2013;20:789–94.